We conclude that TRPV1 antagonists may represent a class of novel anti-diabetic drugs that regulate hyperglycemia and prevent weight gain by ameliorating the low-grade inflammation that is seen in diabetes and in obesity. The gene discussed is TRPV1; the disease is Obesity.